FREE TIPS: DISCOVER PURE NATURAL ORGANIC OILS FOR A HEALTHY SKIN AND WEALTHY LIVING. PURE NATURAL ORGANIC OILS.
LEARN TO BE A SUCCESSFUL NEO LIFE MEMBER

Through clinical observation and treatment of thousands of people with HIV and AIDS, clinical evaluation of the tongues of over 600 people with HIV infection and/or AIDS, and the use of pulse diagnosis, I have come to understand that HIV infection is triggered by Toxic Heat, and initially attacks the Spleen and Stomach Organ Systems. They are the central organs involved in this complex syndrome and must be supported throughout the entire course of the disease even when the HIV-related disharmonies expand to involve all the other organ systems as well.
The Impact of Toxic Heat
Toxic Heat creates the initial flu-like symptoms that for many people accompany initial exposure to HIV. And as the Toxic Heat moves more deeply into all systems of the body, it triggers a whole variety of common HIV-related symptoms: Pruritis (chronic itching), sore throats, increase in body temperature, feeling like you always have a fever even if one is not present, a nagging sensation that something toxic is present in the body.
Toxic Heat is also responsible for the cascade of Organ System disharmonies in the Spleen and Stomach, Kidney and Liver, which contribute to the major complication associated with HIV infection, wasting. (For detailed information on nutritional management and therapy see the Diet Therapy chapter beginning on page? and the three-part Wasting Program: The Daily Diary; The Cleansing Diet; the Anti-Wasting Program in The HIV Wellness Sourcebook.)
Role of the Spleen and Stomach Systems in the Progression from HIV to AIDS
The Spleen and Stomach Systems govern the digestive process, transforming food energy and fluid into Qi and Xue (blood). As a result the Spleen and Stomach moisten and nurture all the other Organ Systems and channels.
When Toxic Heat disrupts the Spleen and Stomach Systems, it triggers symptoms that are associated with the very early stages of HIV infection. These symptoms include:
  • fatigue
  • inability to gain weight no matter how much is eaten
  • stools
  • bloating, gas and flatulence and/or dull pain in the abdomen
  • needing to take naps after meals
  • Frequent infections.
In addition, symptoms of early stage HIV infection, such as dry skin and lips, set in when the flow of fluids and food essence from the Spleen and Stomach to the Lungs, is disrupted. Often dryness in one area, triggers dampness in another: Spleen Qi deficiency with dampness manifests in early neuropathy (a numbness or tingling sensation often in the hands or feet, lymphadenopathy (swelling and inflammation of the lymph nodes), vaginal candidiasis (yeast) infections, more serious loose stools and/or bloating. Spleen-related diarrhea is prevalent with loose stools and abdominal bloating after eating. Skin rashes, commonly associated with early-stage HIV infection, are a result of Spleen Qi deficiency and Lung disharmonies interacting with the essential substances.
Spleen Qi deficiency also causes deficient Xue (blood). Once this sets in, the door is opened to allow Toxic Heat to enter the depleted blood and penetrate ever deeper into the body. The body then moves into more advanced stages of HIV/AIDS. If unchecked, an increasing depletion of the fluids of the Spleen (the Spleen's Yin aspect) leads to overall Yin deficiency, which in turn can lead to Yang depletion.
Although today the combination of Western and Chinese therapies can arrest (for some period of time) the progression of HIV infection to end-stage AIDS for many people, when the cascade of Spleen-Stomach triggered disorders causes overall Yin deficiency and Yang depletion, wasting becomes severe. Diarrhea stops. The skin becomes drier and drier. Thirst is unquenchable. Fevers spike every afternoon and often in the evenings. The pulse is rapid, thready and superficial. This is a terminal stage of HIV disease. (ED: Yes it is called HIV disease.) Acupuncture and herbs are used to support the Shen (spirit) and the passing over to a new phase of existence.
Associated Disharmonies and Opportunistic Infections
Toxic Heat and the Spleen-Stomach disharmonies weaken the body's overall resistance to assault from both internal and external disease factors and allow other organ systems to become involved. This leads to the development of HIV-related disorders and opportunistic infections. For example, if Toxic heat assaults the Lungs, PCP (Pneumocystis Carinii pneumonia) may develop. Xue disharmonies are associated with Kaposi's sarcoma (a proliferative, circulatory cell disease that causes skin lesions); dampness is associated with candidiasis (yeast infections) and fungal invasions; Yin deficiency and Xue deficiency are associated with MAC (Mycobacterium Avian Complex) ; dampness and Spleen and Lung disharmonies may manifest as chronic sinusitis; disturbed Shen that is associated with mental disturbances that accompany HIV/AIDS; and many more.
Each of these syndromes is detailed in the individual treatment programs in the last section of the book. However, I wanted to make the point here that looking at HIV disease as an assault by Toxic Heat that starts with damage to the Spleen and Stomach, and moves on to include other organ systems and Essential Substances, provides a concise method of describing, diagnosing and treating the whole constellation of HIV-related diseases.
China's Tasly Pharmaceutical Group is planning to list its biopharma unit in Hong Kong to raise about $1 billion, in what is likely to be the largest biotech float in the city this year, people with knowledge of the matter said.

TASLY China


The plan comes as Hong Kong Exchanges and Clearing, the city's exchange operator, is proposing changes to its listing rules to woo early-stage drug developers.

Tianjin-based Tasly, well known for producing traditional Chinese medicines, aims to list its wholly owned biopharma arm - Shanghai Tasly Pharmaceutical in the second half of 2018, said the people. Shanghai Tasly is working with advisors on the proposed share sale, they added.

ADVERTISEMENT
Details on the valuation of Shanghai Tasly and what percentage of the company is expected to be floated weren't available, said the people, who declined to be identified as they were not authorized to speak with the media.

The company is yet to decide whether to sell existing shares, or issue new shares, or do a combination of both, the people said.

Tasly and Shanghai Tasly didn't immediately respond to Reuters request for comment.

Shanghai Tasly's planned listing is expected to be the first in a series of biotech firms keen to test the Hong Kong market. Other hopefuls include Chinese biotech company Ascletis, Shanghai Henlius Biotech, a subsidiary of Shanghai Fosun Pharmaceutical, and U.S.-based cancer detection start-up Grail, according to IFR, a Thomson Reuters publication.

Founded in 2001, Shanghai Tasly launched in China one drug aimed at treating blood-clot induced heart attacks, known as pro-UK, in 2012. It is also in the process of developing more than 10 other drugs, according to its website and one of the people.

In a consultation paper published late last month, HKEx said it will allow biotech companies at the pre-revenue stage to list in the city, subject to certain criteria, including that the firms must have developed at least one core product beyond the concept stage.

ADVERTISEMENT

The stock exchange is expected to start accepting listing applications from such companies after the consultation process is concluded in April at the earliest. Currently, China's securities laws do not allow firms that have yet to turn profitable to go public on the mainland.

The plans are part of HKEX's broader move to attract blockbuster Chinese tech companies including Alibaba Group Holding that is already listed in New York, as well as the country's "new economy" companies, which range from biopharma firms to online retailers.

Chinese immunotherapy company BeiGene, Shanghai-based Zai Lab and Hutchison China MediTech, are all listed on Nasdaq, currently the preferred listing venue for mostly as-yet unprofitable biotech drug developers.

Hong Kong is hoping that easing rules for biotech listings and offering concessions to U.S. and UK-listed companies considering a secondary listing in Hong Kong will help it compete with New York and revitalize its IPO market, which has been dominated by Chinese state firms, other financial and property groups.

Shanghai Tasly is also considering a pre-IPO fundraising, said two of the people, although the size of the financing hasn't been finalised.

Popular Posts

Subscribe to TASLY HEALTH PRODUCTS by Email Follow me on Twitter!